How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (fanxh@zju.edu.cn)

    Website using assistance : Leihong Wu (11019004@zju.edu.cn)



    Basic Information

    Gene Name: KCNH2

    Description: "potassium voltage-gated channel, subfamily H (eag-related), member 2"

    Entrez Gene ID: 3757

    SwissProt Acc Number: Q12809

    RefSeq: NM_000238

    It was suspected to be CHD related:

    ..We report a new genetic variation (rs1805120) in the KCNH2 gene that predisposes Chinese Han individuals to the risk of acquired AF. ..

    From PMID: 19490382, in Journal J Cardiovasc Electrophysiol.? , 2009


    References

    There were 2 potential papers with KCNH2 and CHD.

    PMIDTitleJournalsDetails
    21410720 Mutation analysis ion channel genes ventricular fibrillation survivors with coronary artery disease.Pacing and clinical electrophysiology : PACEMore Details
    19490382 Genetic polymorphism of KCNH2 confers predisposition of acquired atrial fibrillation in Chinese.Journal of cardiovascular electrophysiologyMore Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.



    PPI interactions

    There were totally 18 unique genes interacted with KCNH2. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    CDC73 Two-hybrid16169070|16169070 No
    NDUFS6 Two-hybrid16169070|16169070 No
    CAV3 Affinity Capture-Western22879586 CHD related
    NEDD4L Affinity Capture-Western22879586 No
    YWHAH in vitro;in vivo11953308 No
    ALG10B Affinity Capture-Western14525949|14525949 No
    YWHAE Reconstituted Complex11953308|11953308|11953308 No
    KCNE1 Affinity Capture-Western9230439|9230439 CHD related
    UBC Affinity Capture-Western21177251|19726881|22879586 No
    HSPA4 Affinity Capture-Western12775586 No
    HSP90AA1 Affinity Capture-Western12775586 CHD related
    CUL1 Affinity Capture-MS21145461 No
    CANX Affinity Capture-Western22242185 No
    CALR Affinity Capture-Western22242185 No
    RHOH yeast 2-hybrid16169070 No
    PRKACA in vitro11953308,10837251 CHD related
    KCNE2 in vivo11278781 CHD related
    ALG10 in vivo14525949 No


    Involved FDA drugs

    StatusDrubBank IDNameIndicationATC Code
    approvedDB00204DofetilideFor the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythmC01BD04
    approvedDB00276AmsacrineFor treatment of acute myeloid leukaemia.L01XX01
    approvedDB00308IbutilideIndicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.C01BD05
    approved;withdrawnDB00342Terfenadine"For the treatment of allergic rhinitis, hay fever, and allergic skin disorders."R06AX12
    approvedDB00457Prazosin"For treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. "C02CA01
    approvedDB00489SotalolFor the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.C07AA07;C07AA57
    approvedDB00590DoxazosinFor treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.C02CA04
    approved;withdrawnDB00604CisaprideFor the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.A03FA02
    approved;withdrawnDB00637Astemizole"Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias."R06AX11
    approvedDB00661Verapamil"For the treatment of hypertension, angina, and cluster headache prophylaxis."C08DA01
    approvedDB00679ThioridazineFor the treatment of schizophrenia and generalized anxiety disorder.N05AC02
    approvedDB00908QuinidineFor the treatment of ventricular pre-excitation and cardiac dysrhythmiasC01BA01
    approvedDB01100PimozideUsed for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.N05AG02
    approvedDB01110Miconazole"For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, and <i>Epidermophyton floccosum</i>, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor."A01AB09;A07AC01;D01AC02;G01AF04;J02AB01;S02AA13
    approvedDB01118Amiodarone"Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia."C01BD01
    approvedDB01136CarvedilolFor the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.C07AG02
    approvedDB01162TerazosinFor the treatment of symptomatic BPH and mild to moderate hypertension.G04CA03
    approvedDB01182Propafenone"Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia."C01BC03
    approvedDB01218HalofantrineFor treatment of Severe malariaP01BX01
    approved;withdrawnDB06144SertindoleUsed in the treatment of schizophrenia.N05AE03